Company intelligence / Profile preview

Appia Bio

Culver City / Los Angeles area, California, United Statesappiabio.com ↗

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

No published clinical results yet. The company has raised significant funding ($52M Series A) to advance its lead programs toward the clinic, focusing on scalable off-the-shelf allogeneic cell therapies for cancer using their proprietary ACUA platform.

Therapeutic areas: Oncology
Modalities: Allogeneic cell therapies (off-the-shelf)CAR-iNKT cells (Chimeric Antigen Receptor invariant Natural Killer T cells)HSC-derived cell therapies (from hematopoietic stem cells)TCR gene engineering
Industry: Biotech

Drug pipeline

1 asset

Allo15MCAR-NKT

Preclinical

Partnerships

Gilead Sciences/Kite Pharma — collaboration and license agreement to develop HSC-derived allogeneic cell therapies for blood cancers. Deal value up to $875 million plus royalties.

Beyond the preview

Go deeper on Appia Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Appia Bio.

Explore the full profile